Lupin Enters into Patent Licensing Agreement with Takeda to Commercialize Vonoprazan in India

Global pharma major Lupin Limited has entered into a non-exclusive patent license agreement with Takeda Pharmaceutical Company Limited to commercialize Vonoprazan Tablets in the Indian market. The drug will be marketed under the brand name Lupin’s Lupivon® and will be available in two strengths - 10 mg and 20 mg. Vonoprazan is a novel potassium-competitive acid blocker (P-CAB) with unique attributes like complete proton pump inhibition with the first dose, longer duration of action, and meal-independent dosing. It is approved by the DCGI for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment. Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets.